|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-17.38/1.75
|
企業價值
1.56B
|
資產負債 |
每股賬面淨值
1.15
|
現金流量 |
現金流量率
--
|
損益表 |
收益
1.21B
|
每股收益
4.04
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/17 00:52 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, initially focusing on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy. |